Список литературы

1. , J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology 2010, 138, 2101 - 2114

2. Johns, L.E.; Houlston, R.S. A systematic review and meta-analysis of familial colorectal cancer risk. Am. J. Gastroenterol. 2001, 96, 2992 - 3003.

3. Tenesa, A.; Dunlop, M.G. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat. Rev. Genet. 2009, 10, 353 - 358.

4. Huxley, R.R.; Ansary-Moghaddam, A.; Clifton, P.; Czernichow, S.; Parr, C.L.; Woodward, M. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: A quantitative overview of the epidemiological evidence. Int. J. Cancer 2009, 125, 171 - 180.

5. Watson, A.J.M.; Collins, P.D. Colon cancer: A civilization disorder. Dig. Dis. 2011, 29, 222 - 228.

6. Meyerhardt, J.A.; Catalano, P.J.; Haller, D.G.; Mayer, R.J.; Macdonald, J.S.; Benson, A.B.; Fuchs, C.S. Impact of diabetes mellitus on outcomes in patients with colon cancer. J. Clin. Oncol. 2003, 21, 433 - 440.

7. Hjartaker A. et al. Subsite-specific dietary risk factors for colorectal cancer: a review of cohort studies. J Oncol 2013, Article ID 703854, 14 pages (2013).

8. Theodoratou E. et al. Associations between dietary and lifestyle risk factors and colorectal cancer in the Scottish population. Eur J Cancer Prev 23, 8 - 17 (2014).

9. Rasool S., Kadla S.A., Rasool V. & Ganai B.A. A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumor Biol 34, 2469 - 2476 (2013).

10. Esposito K. et al. Colorectal cancer association with metabolic syndrome and its components: A systematic review with meta-analysis. Endocrine 44, 634 - 647 (2013).

11. Larsson S.C., Orsini N. & Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97, 1679 - 1687 (2005)

12. Raskov H., Pommergaard H.C., Burcharth J. & Rosenberg J. Colorectal carcinogenesis--update and perspectives. World J Gastroentero 20, 18151 - 18164 (2014)

13. Donohoe C, O'farrell N, Doyle S, Reynolds J (2014). The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol, 7, 38 - 50.

14. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2014 г.//Издательская группа РОНЦ. 2016. - 217 С.

15. Finan PJ, Ritchie JK, Hawley PR. Synchronous and "early" metachronous carcinomas of the colon and rectum. Br J Surg 1987; 74: 945 - 47.

16. Barillari P, Ramacciato G, De Angelis R et al. Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms, Acta Chir Scand 1990; 156: 163 - 166

17. Computed tomographic colonography compared with colonoscopy or barium enema for diagnosis of colorectal cancer in older symptomatic patients: two multicentre randomised trials with economic evaluation (the SIGGAR trials). Health Technol Assess. 2015 Jul; 19 (54): 1 - 134. (https://www.ncbi.nlm.nih.gov/pubmed/26198205)

18. Starck M, Bohe M, Simanaitis M, Valentin L. Rectal endosonography can distinguish benign rectal lesions from invasive early rectal cancers. Colorectal Dis. 2003 May; (3): 246 - 50. (https://www.ncbi.nlm.nih.gov/pubmed/26198205)

Niekel MC, Bipat S, Stoker J, et al. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010 Dec; 257 (3): 674 - 84. (https://www.ncbi.nlm.nih.gov/pubmed/26198205)

20. Lee EJ, Lee JB, Lee SH, et al. (https://www.ncbi.nlm.nih.gov/pubmed/26198205) Endoscopic submucosal dissection for colorectal tumors--1,000 colorectal ESD cases: one specialized institute"s experiences. Surg Endosc. 2013 Jan; 27 (1): 31 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

21. Федянин М.Ю., Трякин А.А., Тюляндин С.А. Адъювантная химиотерапия рака толстой кишки.//Фарматека N 7(220) 2011, с. 21 - 27. (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

22. Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery. 1986 Aug; 100 (2): 278 - 84. (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

23. Oshowo A, Gillams A, Harrison E, et al. Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg. 2003 Oct; 90(10): 1240-3 (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

24. Falcone A., Cremolini C., Masi G., et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. J Clin Oncol. 31, 2013 (suppl; abstr 3505). (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

25. Федянин М.Ю., Трякин А.А., Тюляндин С.А. Потенциальные предикторы эффективности анти-EGFR-терапии при метастатическом раке толстой кишки.//Онкологическая колопроктология 2013, N 2, стр. 21 - 30. (https://www.ncbi.nlm.nih.gov/pubmed/22729707/)

26. Landmann RG, (http://www.ncbi.nlm.nih.gov/pubmed?term=) Weiser MR. (http://www.ncbi.nlm.nih.gov/pubmed?term=) Clin Colon Rectal Surg. 2005 Aug; 18 (3): 182 - 9. Surgical management of locally advanced and locally recurrent colon cancer. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

27. KF, Matos D, P. Cochrane Database Syst Rev. 2011 Sep 7; (9): CD001544. Epub 2011 Sep 7) (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

28. van der Pas M. H. G. M. et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial//The lancet oncology. - 2013. - T. 14. - N. 3. - C. 210 - 218. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

29. Kang S. B. et al. Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial //The lancet oncology. - 2010. - T. 11. - N. 7. - C. 637 - 645. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

30. Jeong S. Y. et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial//The Lancet Oncology. - 2014. - T. 15. - N. 7. - C. 767 - 774. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

31. Green B. L. et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer //British Journal of Surgery. - 2013. - T. 100. - N. 1. - C. 75 - 82. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

32. De Salvo GL, Gava C, Lise M et al. Curative surgery for obstruction from primary left colorectal carcinoma: Primary or staged resection. The Cochrane Database of Systematic Reviews 2006 Issue 2 (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

33. Khot UP, Lang AW, Murali K, Parker MC. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89 (9): 1096 - 1020. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

34. Meyer F, Marusch F, Coch A, Meyer L, Fuhrer S, Kockerling F, et al. the German Study Group 'Colorectal Carcinoma (Primary Tumor)' Emergency operation in carcinomas of the left colon: value of Hartmann"s procedure. Tech Coloproctol. 2004; 8: S226 - 9 (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

35. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143 - 152. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

36. Cunningham D, Sirohi B, Pluzanska A et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244 - 250. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

37. Ackland SP, Jones M, Tu D et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Br J Cancer 2005; 93: 1236 - 1243 (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

38. Schmoll HJ, Van Cutsem E, Stein A et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479 - 2516. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

39. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229 - 237. (http://www.ncbi.nlm.nih.gov/pubmed/20011301)

40. Rosa B, (https://www.ncbi.nlm.nih.gov/pubmed/?term=Rosa%20B%5BAuthor%5D&cauthor=true&cauthor_uid=26557880) de Jesus JP, (https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Jesus%20JP%5BAuthor%5D&cauthor=true&cauthor_uid=26557880) de Mello EL, et al. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis, (https://www.ncbi.nlm.nih.gov/pubmed/?term=de%20Mello%20EL%5BAuthor%5D&cauthor=true&cauthor_uid=26557880) Ecancermedicalscience. 2015 Oct 15; 9: 582. (https://www.ncbi.nlm.nih.gov/pubmed/26557880)

41. Bayraktar B, Ozemir IA, Kefeli U, et al. (https://www.ncbi.nlm.nih.gov/pubmed/26557880) Colorectal stenting for palliation and as a bridge to surgery: A 5-year follow-up study. World J Gastroenterol. 2015 Aug 21; 21 (31): 9373 - 9. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

42. Glynne-Jones R., Tan D., Goh V. Pelvic MRI for guiding treatment decisions in rectal cancer//Oncology. - 2014. - T. 28. - N. 8. - C. 667 - 667. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

43. Brown G. et al. Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging//British Journal of Surgery. - 2003. - T. 90. - N. 3. - C. 355 - 364. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

44. Lee J. H. et al. Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02//Radiotherapy and Oncology. - 2014. - T. 113. - N. 1. - C. 18 - 23. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

45. Algebally A. M. et al. The Value of High-Resolution MRI Technique in Patients with Rectal Carcinoma: Pre-Operative Assessment of Mesorectal Fascia Involvement, Circumferential Resection Margin and Local Staging//Polish Journal of Radiology. - 2015. - T. 80. - C. 115. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

46. Vliegen R. F. A. et al. Rectal Cancer: MR Imaging in Local Staging - Is Gadolinium-based Contrast Material Helpful? 1//Radiology. - 2005. - T. 234. - N. 1. - C. 179 - 188. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

47. Glimelius B. et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up //Annals of oncology. - 2013. - T. 24. - N. suppl 6. - C. vi81 - vi88. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

48. Nascimbeni R. et al. Long-term survival after local excision for T1 carcinoma of the rectum//Diseases of the colon & rectum. - 2004. - T. 47. - N. 11. - C. 1773 - 1779. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

49. Sgourakis G. et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes//The American surgeon. - 2011. - T. 77. - N. 6. - C. 761 - 772. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

50. Doornebosch P. G., Tollenaar R., de Graaf E. J. R. Is the increasing role of transanal endoscopic microsurgery in curation for T1 rectal cancer justified?//PG Doornebosch. - C. 9. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

51. Wong R. K. S. et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma//The Cochrane Library. - 2007. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

52. Mathis K. L. et al. Unresectable colorectal cancer can be cured with multimodality therapy //Annals of surgery. - 2008. - T. 248. - N. 4. - C. 592 - 598. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

53. Yin Z. et al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): Simultaneous or delayed?//Hepatology. - 2013. - T. 57. - N. 6. - C. 2346 - 2357. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

54. Feng O. et al. Timing of Hepatectomy for Resectable Synchronous Colorectal Liver Metastases: For Whom Simultaneous Resection Is More Suitable-A Meta-Analysis//PLoS one. - 2014. - T. 9. - N. 8. - C. e 104348. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

55. Garden O. J. et al. Guidelines for resection of colorectal cancer liver metastases//Gut. - 2006. - T. 55. - N. suppl 3. - C. iii1 - iii8. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

56. K. F., Matos D., P. Mechanical bowel preparation for elective colorectal surgery//The Cochrane Library. - 2011. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

57. Heald R. J. et al. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978 - 1997//Archives of Surgery. - 1998. - T. 133. - N. 8. - C. 894 - 898. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

58. Havenga K. et al. Anatomical basis of autonomic nerve-preserving total mesorectal excision for rectal cancer//British journal of surgery. - 1996. - T. 83. - N. 3. - C. 384 - 388. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

59. Martin S.T., Heneghan H.M., Winter D.C. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer//British Journal of Surgery. - 2012. - T. 99. - N. 7. - C. 918 - 928. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

60. Ceelen W. P., Van Nieuwenhove Y., Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer//The Cochrane Library. - 2009. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

61. Stornes T, Wibe A, Nesbakken A et al. National early rectal cancer treatment revisited. Dis Colon Rectum 2016; 59: 623 - 629 (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

62. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ. 2006; 333: 779 (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

63. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. British journal of cancer. 2000 Jun; 82 (11): 1789. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

64. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clinical epidemiology. 2012; 4: 283. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

65. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, DalPOlio FG, Barbera MA, Pantaleo MA, Biasco G. Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World journal of gastroenterology. 2016 Jan 14; 22 (2): 519. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

66. Chua TC, Saxena A, Liauw W, Kokandi A, Morris DL. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Annals of surgical oncology. 2010 Feb 1; 17 (2): 492 - 501. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

67. Primrose J, Falk S, Finch-Jones M, Valle J, O"Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. The lancet oncology. 2014 May 1; 15 (6): 601 - 11. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

68. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307: 1383 - 1393, 2012 (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

69. Allegra CJ, Yothers G, O'Connell MJ, et al: Bevacizumab in stage II - III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 31: 359 - 364, 2013 (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

70. Jonker D, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Groupof Cancer Care Ontario's Program in Evidence-Based Care. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first-and second-line treatment of advanced colorectal cancer. Current Oncology. 2006 Oct; 13 (5): 173. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

71. Teixeira MC, Marques DF, Ferrari AC, Alves MF, Alex AK, Sabbaga J, Hoff PM, Riechelmann RP. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4. Clinical colorectal cancer. 2015 Mar 1; 14 (1): 52 - 7. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

72. Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, SD, Guren MG. Palliative pelvic radiotherapy for symptomatic rectal cancer-a prospective multicenter study. Acta Oncologica. 2016 Dec 1; 55 (12): 1400 - 7. (https://www.ncbi.nlm.nih.gov/pubmed/26309363)

73. Lee CW, Bociek G, Faught W. A survey of practice in management of malignant ascites. J Pain Symptom Manage. 1998; 16: 96 - 101 (https://www.ncbi.nlm.nih.gov/pubmed/26309363)